MXPA02001803A - Metodos de coformulacion y sus productos. - Google Patents

Metodos de coformulacion y sus productos.

Info

Publication number
MXPA02001803A
MXPA02001803A MXPA02001803A MXPA02001803A MXPA02001803A MX PA02001803 A MXPA02001803 A MX PA02001803A MX PA02001803 A MXPA02001803 A MX PA02001803A MX PA02001803 A MXPA02001803 A MX PA02001803A MX PA02001803 A MXPA02001803 A MX PA02001803A
Authority
MX
Mexico
Prior art keywords
coformulation
active
products
methods
amorphous
Prior art date
Application number
MXPA02001803A
Other languages
English (en)
Inventor
Scott Harland Ronald
Original Assignee
Bradford Particle Design Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bradford Particle Design Ltd filed Critical Bradford Particle Design Ltd
Publication of MXPA02001803A publication Critical patent/MXPA02001803A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D11/00—Solvent extraction
    • B01D11/04—Solvent extraction of solutions which are liquid
    • B01D11/0403—Solvent extraction of solutions which are liquid with a supercritical fluid
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D11/00—Solvent extraction
    • B01D11/04—Solvent extraction of solutions which are liquid
    • B01D11/0403—Solvent extraction of solutions which are liquid with a supercritical fluid
    • B01D11/0407—Solvent extraction of solutions which are liquid with a supercritical fluid the supercritical fluid acting as solvent for the solute
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D11/00—Solvent extraction
    • B01D11/04—Solvent extraction of solutions which are liquid
    • B01D11/0403—Solvent extraction of solutions which are liquid with a supercritical fluid
    • B01D11/0411—Solvent extraction of solutions which are liquid with a supercritical fluid the supercritical fluid acting as solvent for the solvent and as anti-solvent for the solute, e.g. formation of particles from solutions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D11/00—Solvent extraction
    • B01D11/04—Solvent extraction of solutions which are liquid
    • B01D11/0488—Flow sheets

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una coformulacion de una sustancia activa (de preferencia una sustancia farmaceuticamente activa, por ejemplo un inhibidor de la enzima COX-2) y un excipiente oligomerico o polimerico, que contiene por lo menos 10% de la sustancia activa, de la cual entre el 80 y el 100% es amorfa. La fase amorfa es estable, con respecto a su fase o fases cristalinas, durante por lo menos tres meses despues de su preparacion cuando se almacena a una temperatura entre 0 y 10¦C. La invencion tambien provee procedimientos, que de preferencia impliquen la formacion de particulas mediante procedimiento SEDSTM, para preparar dicha coformulacion.
MXPA02001803A 1999-08-31 2000-08-31 Metodos de coformulacion y sus productos. MXPA02001803A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9920558.5A GB9920558D0 (en) 1999-08-31 1999-08-31 Methods for particle formation and their products
PCT/GB2000/003328 WO2001015664A2 (en) 1999-08-31 2000-08-31 Coformulation methods and their products

Publications (1)

Publication Number Publication Date
MXPA02001803A true MXPA02001803A (es) 2004-02-26

Family

ID=10860085

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02001803A MXPA02001803A (es) 1999-08-31 2000-08-31 Metodos de coformulacion y sus productos.

Country Status (8)

Country Link
EP (1) EP1207856A2 (es)
JP (1) JP2003508419A (es)
KR (1) KR20020047137A (es)
AU (1) AU783570B2 (es)
CA (1) CA2382556A1 (es)
GB (2) GB9920558D0 (es)
MX (1) MXPA02001803A (es)
WO (1) WO2001015664A2 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ513964A (en) 1999-12-08 2004-01-30 Pharmacia Corp Solid-state form of celecoxib having enhanced bioavailability
CH694686A5 (it) 2000-03-04 2005-06-15 Eco2 Sa Prodotto di micronizzazione di sostanze farmaceutiche.
FR2815540B1 (fr) † 2000-10-19 2005-06-10 Separex Sa Procede de fabrication de tres fines particules constituees d'un principe insere dans une molecule hote
GB0027357D0 (en) 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
GB0102075D0 (en) 2001-01-26 2001-03-14 Astrazeneca Ab Process
EP1401404B1 (en) 2001-05-30 2008-04-16 Csir Method of encapsulating an active substance
US20050271737A1 (en) * 2001-06-07 2005-12-08 Chinea Vanessa I Application of a bioactive agent to a substrate
US20050260273A1 (en) * 2001-06-07 2005-11-24 Chinea Vanessa I Applicatin of a bioactive agent in a solvent composition to produce a target particle morphology
US7767249B2 (en) * 2001-06-07 2010-08-03 Hewlett-Packard Development Company, L.P. Preparation of nanoparticles
BR0210518A (pt) 2001-06-22 2004-06-22 Pfizer Prod Inc Composições farmacêuticas de dispersões de drogas e polìmeros neutros
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
RU2309160C2 (ru) 2001-10-22 2007-10-27 Домпе фа. р. ма с.п.а. Способ получения микрочастиц белка или полипептида и продукт
US8524279B2 (en) 2001-11-01 2013-09-03 Novartis Ag Spray drying methods and related compositions
EP1469832B2 (en) 2002-02-01 2016-10-26 Bend Research, Inc. Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
CA2524773C (en) 2003-05-08 2014-04-08 Nektar Therapeutics Uk Ltd Particulate coformulations of active substances with excipients
CA2532931A1 (en) 2003-08-04 2005-02-10 Pfizer Products Inc. Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials
US7507823B2 (en) 2004-05-06 2009-03-24 Bristol-Myers Squibb Company Process of making aripiprazole particles
WO2008070279A2 (en) 2006-10-11 2008-06-12 Crititech, Inc. Method for precipitation of small medicament particles into use containers
GB0702402D0 (en) 2007-02-08 2007-03-21 Thar Pharmaceuticals Inc Method of creating crystalline substances
WO2008097664A1 (en) 2007-02-11 2008-08-14 Map Pharmaceuticals, Inc. Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile
CA2706684C (en) 2007-12-07 2016-01-12 Xspray Microparticles Ab Method and arrangement for the production of particles
GB0812742D0 (en) 2008-07-11 2008-08-20 Critical Pharmaceuticals Ltd Process
US9808030B2 (en) 2011-02-11 2017-11-07 Grain Processing Corporation Salt composition
ES2854751T3 (es) * 2012-01-13 2021-09-22 Xspray Microparticles Ab Un procedimiento para producir nanopartículas híbridas amorfas estables que comprende al menos un inhibidor de la proteína cinasa y al menos un componente polimérico estabilizante y formador de matriz
FI3181128T3 (fi) * 2012-01-13 2023-06-02 Xspray Pharma Ab Publ Nilotinibin farmaseuttinen koostumus

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1146866A (en) * 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
EP0462066A1 (en) * 1990-06-15 1991-12-18 Warner-Lambert Company Amorphous gemfibrozil
DE4041563A1 (de) * 1990-12-22 1992-06-25 Sanol Arznei Schwarz Gmbh Verfahren zur herstellung wirkstoffhaltiger mikropartikel aus hydrolytisch abbaubaren polymeren
IT1255792B (it) * 1992-08-05 1995-11-16 Bayer Italia Spa Composizioni farmaceutiche per la somministrazione orale di diidropiridine in forma di bevanda
GB9313642D0 (en) * 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
US5773025A (en) * 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
IE75744B1 (en) * 1995-04-03 1997-09-24 Elan Corp Plc Controlled release biodegradable micro- and nanospheres containing cyclosporin
SI9500173B (sl) * 1995-05-19 2002-02-28 Lek, Trofazna farmacevtska oblika s konstantnim in kontroliranim sproščanjem amorfne učinkovine za enkrat dnevno aplikacijo
TW487582B (en) * 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
AU709384B2 (en) * 1996-03-01 1999-08-26 University Of Kansas, The Methods and apparatus for particle precipitation and coating using near-critical and supercritical antisolvents
HUP9902889A3 (en) * 1996-05-17 2002-04-29 Merck Frosst Canada & Co Kirkl The use of 3-phenyl-4-(4-methylsulphonyl)-phenyl-2-(5h)-furanone for producing anti inflammatory medicaments and such medicaments
FR2753639B1 (fr) * 1996-09-25 1998-12-11 Procede de preparation de microcapsules de matieres actives enrobees par un polymere et nouvelles microcapsules notamment obtenues selon le procede
US5980942A (en) * 1997-01-23 1999-11-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Zero-order sustained release matrix tablet formulations of carbamazepine
IT1296464B1 (it) * 1997-11-19 1999-06-25 Vectorpharma Int Composizioni farmaceutiche in forma di polveri di polimeri reticolati caricati con farmaci e relativo processo di preparazione mediante
DE19821951A1 (de) * 1998-05-15 1999-11-18 Basf Ag Cyclosporin-Zubereitungen
US6465011B2 (en) * 1999-05-29 2002-10-15 Abbott Laboratories Formulations comprising lipid-regulating agents
GB9915975D0 (en) * 1999-07-07 1999-09-08 Bradford Particle Design Ltd Method for the formation of particles

Also Published As

Publication number Publication date
EP1207856A2 (en) 2002-05-29
GB0021227D0 (en) 2000-10-18
GB2355194B (en) 2003-01-08
AU783570B2 (en) 2005-11-10
GB2355194A (en) 2001-04-18
JP2003508419A (ja) 2003-03-04
KR20020047137A (ko) 2002-06-21
GB9920558D0 (en) 1999-11-03
AU6855000A (en) 2001-03-26
CA2382556A1 (en) 2001-03-08
WO2001015664A2 (en) 2001-03-08
WO2001015664A3 (en) 2001-09-20

Similar Documents

Publication Publication Date Title
MXPA02001803A (es) Metodos de coformulacion y sus productos.
EP1728791A4 (en) COMPOSITIONS FOR SOLID PHARMACEUTICAL PREPARATION OF SOLIFENACIN OR BZW. A SALT OF IT
NO2005025I1 (no) Krystalinsk ceftiofurfri syre, fremgangsmate for fremstilling av denne, og farmasoytisk preparat
AU2681300A (en) Solid oral dosage form containing an enhancer
HUP0101281A3 (en) Diphenyl-piperidine butanamides as glycine transport inhibitors, process for producing them, use of them for producing medicaments and the pharmaceutical compositions containing them
AU6328094A (en) Saccharin derivative proteolytic enzyme inhibitors
AU2829292A (en) Saccharin derivative proteolytic enzyme inhibitors
AU2001276420A1 (en) Novel gamma crystalline form of perindopril tert-butylamine salt, preparation method, and pharmaceutical compositions containing same.
YU24402A (sh) 2'-supstituisani 1,1'-bifenil-2-karbonamidi, postupak za njihovu proizvodnju, njihova primena kao leka kao i farmaceutski preparati koji sadrže ta jedinjenja
GEP20043179B (en) Halogenated Amidino Amino Acid Derivatives Useful as Nitric Oxide Synthase Inhibitors
AU2001234107A1 (en) Benzoic acid derivatives, process for producing the same and drugs containing the same as the active ingredient
AU5290199A (en) Erythromycin derivatives with antibiotic activity
AU1031697A (en) Novel geranylgeranyl-derivatives, process for the preparation thereof and related pharmaceutical compositions
CA2292629A1 (en) Composition comprising 5-¬4-¬2-(n-methyl-n-2-pyridyl)amino)ethoxy|benzyl|thiazolidine-2,4-dione
HUP0202322A2 (en) A substantially crystalline form of melagatran, process for obtaining it, pharmaceutical composition containing thereof and its use
AU9270498A (en) Tricyclic compounds, preparation method and said method intermediates, appl ication as medicines and pharmaceutical compositions containing same
AU2566101A (en) Compounds and methods for the treatment of pain
AU9270598A (en) Hydrazono-benzazulene derivatives, pharmaceutical compositions and in termediates
AU2137192A (en) Substituted mandelic acid derivatives, processes for their preparation and their use in medicaments
AU7316600A (en) Process for the preparation of cyclic lactic acid oligomers
AU7316700A (en) Process for the preparation of cyclic lactic acid oligomers
AU2001284476A1 (en) Novel crystals of 1,3,4-oxadiazole derivative, process for producing the crystals and medicines containing the same as the active ingredient
AU2002325614A1 (en) Compounds containing lactic acid elements, method for the production and use thereof as pharmaceutically active substances
WO2002006299A3 (en) Therapeutic uses for aminosterol compounds
AU6870500A (en) Process for the preparation of 2,3-dihydroazepine derivatives

Legal Events

Date Code Title Description
HC Change of company name or juridical status
FG Grant or registration